Actively Recruiting
Augmented Response of Volatile Biomarkers in Assessment of Oesophagogastric Cancer (AROMA 1 / BIORESOURCE)
Led by Imperial College London · Updated on 2025-01-31
648
Participants Needed
1
Research Sites
187 weeks
Total Duration
On this page
Sponsors
I
Imperial College London
Lead Sponsor
I
Imperial College Healthcare NHS Trust
Collaborating Sponsor
AI-Summary
What this Trial Is About
Cancer of the stomach and oesophagus is among the world's top five cancers. Survival rates are very poor as the disease presents late and early symptoms are non-specific. The study team has developed a non-invasive test for cancers of the stomach and oesophagus based on the detection of volatile organic compounds in exhaled breath. These compounds are known to be produced by both cancers as well as cancer associated bacteria within the gut. The proposed innovation is to improve the accuracy of this test by investigating whether simple metabolic substrates can increase the production of these volatile organic compounds by both the tumour and its associated bacteria.
CONDITIONS
Official Title
Augmented Response of Volatile Biomarkers in Assessment of Oesophagogastric Cancer (AROMA 1 / BIORESOURCE)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 to 90 years
- Participants with biopsy-proven adenocarcinoma of the esophagus or stomach who are treatment-naive (for cancer cohorts)
- Participants with normal or benign upper gastrointestinal disease confirmed by endoscopy within 1 year or with planned endoscopy (for control cohorts)
You will not qualify if you...
- Diagnosis of esophageal squamous cell carcinoma
- Previous surgery removing part of the esophagus or stomach
- Received neoadjuvant chemotherapy for esophageal or gastric cancer
- History of another cancer within 3 years (AROMA 1) or 5 years (BIORESOURCE)
- Any form of esophageal dysplasia (control cohorts)
- Previously diagnosed Barrett's esophagus (control cohorts)
- Active infection, use of immunosuppressive medication, or antibiotic therapy within the last 8 weeks
- Co-morbidities preventing breath collection
- Allergies to any ingredients of the nutrient drink including glucose, glycerol, iron sulphate, maltodextrin (corn, potato), xanthan gum, potassium chloride, tyrosine, phenylalanine, and glutamic acid (AROMA 1 only)
- Unable or unwilling to provide informed written consent
- Pregnant participants
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Imperial College NHS Foundation Trust
London, United Kingdom, W12 0HS
Actively Recruiting
Research Team
A
Ayushi Pabari, BSc, MSc
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here